Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).
Lin
H-C
HC
Lu
P-L
PL
Chang
C-H
CH
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000009:adverse effects*; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D061466:Lopinavir; D008297:Male; D015864:Panuveitis / Q000139:chemically induced*; D011744:Pyrimidinones / Q000009:adverse effects; D017828:Rifabutin / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D011744:Pyrimidinones; D017828:Rifabutin; D061466:Lopinavir; D019438:Ritonavir